Efficacy and Safety of GLP-1 and Dual GIP/GLP-1 Receptor Agonists in Idiopathic Intracranial Hypertension: A Systematic Review and Meta-Analysis.

ABSTRACT:

Background

Repurposing glucagon-like peptide-1 (GLP-1) and GIP/GLP-1 receptor agonists (RAs) for idiopathic intracranial hypertension (IIH) represents an attractive alternative to current treatments, supported by evidence of potent metabolic effects and reductions in cerebrospinal fluid secretion and intracranial pressure in vivo.

Methods

We evaluated the safety and efficacy of GLP-1 RAs and GIP/GLP-1 RAs in IIH. MEDLINE and Scopus databases were searched for randomized-controlled trials (RCT), non-randomized clinical trials, or registries in adults with IIH.

Results

Two clinical trials (one RCT and one non-randomized case-control) and two registries, comprising 1550 IIH patients (768 receiving GLP-1 or GIP/GLP-1 RAs) were included. Compared with standard-of-care, GLP

SUBMITTER: Stefanou MI 

PROVIDER: S-EPMC12426903 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature